araag2/HINT huggingface dataset:
Clinical trial NCT00641745 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: lurasidone hcl, risperidone
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Main Inclusion Criteria:

        To be eligible to enter the study, each patient must comply with the following inclusion
        criteria:

          -  Subject is 18 to 75 years on the day of signing the consent form (age parameters may
             be restricted further per local requirements without protocol amendment).

          -  Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
             (DSM-IV) criteria for a primary diagnosis of schizophrenia (including disorganized
             (295.10), paranoid (295.30), undifferentiated (295.90), catatonic (295.20), or
             residual (295.60) or schizoaffective disorder (295.70) subtypes.

          -  Subject is not pregnant or nursing, and is not planning pregnancy within the projected
             duration of the study.

          -  Subject will comply with the study procedures and outpatient visit requirements in the
             opinion of the investigator.

          -  Subject voluntarily agrees to participate in the study by giving written informed
             consent.

        Main Exclusion Criteria:

        To be excluded from entering this study if they fulfil any of the criteria below:

          -  Subject has a chronic organic disease of the central nervous system (other than
             schizophrenia).

          -  Subject has current clinically significant or history of, alcohol abuse/alcoholism or
             drug abuse/dependence within the last 6 months.

          -  In the opinion of the investigator, the subject has any condition, therapy, laboratory
             abnormality, or other circumstance that might confound the results of the study, or
             interfere with the subject's participation for the full duration of the study.

          -  Subject has participated in a study with an investigational compound or device within
             30 days of signing informed consent.
Clinical trial NCT00536081 (phase 3, status: completed)
Conditions: breast cancer, chemotherapy, febrile neutropenia
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: pegfilgrastim
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Breast cancer patients ≥18 years.

          -  Indication for 3-weekly chemotherapy.

          -  Considered fit enough to receive chemotherapy, with adequate renal and hepatic
             function.

          -  Planned a chemotherapy regime in adjuvant, neo-adjuvant, advanced setting with an
             increased risk of febrile neutropenia, i.e.:

          -  Regimes with >20% risk of febrile neutropenia:

               -  e.g. TAC (docetaxel, adriamycin, cyclophosphamide)

               -  AT (adriamycin, docetaxel)

          -  Regimes with 10-20% risk of febrile neutropenia (e.g. AC, doxorubicin and vinorelbine,
             or docetaxel monotherapy) in the presence of ≥1 patient risk factor (>65 yrs,
             extensive bone marrow involvement or prior extensive radiotherapy on bone tissue

          -  Prior chemotherapy

          -  ECOG performance status of 2 or more, grade 2 or higher liver function abnormalities).

          -  That is, patients starting with docetaxel as second part of FEC-D are eligible for the
             last 3 docetaxel cycles, if there is an increased risk of febrile neutropenia, e.g. by
             elderly age.

          -  Able to comply with the protocol.

          -  Written informed consent obtained prior to any study specific screening.

        Exclusion Criteria:

          -  Active uncontrolled infection.

          -  Inadequate renal or hepatic function.

          -  Any evidence or history of hypersensitivity or other contraindications to G-CSF
             medication.

          -  Not recovered from acute toxicities of prior therapies.

          -  Absolute neutrophil count (ANC) <1.5 x 109/l, not caused by bone marrow involvement.
Clinical trial NCT00624065 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: carvedilol controlled release/lisinopril, lisinopril + placebo
SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female age 18-80 years; stage 1 or 2 hypertension currently receiving 0 or 1
             antihypertensive medication; mean sitting systolic blood pressure >/=140mmHg to
             </=170mmHg, or mean sitting diastolic blood pressure >/=90 to </=105mmHg. Subjects
             taking one hypertensive medication had their medication withdrawn and entered a
             wash-out phase prior to randomization.

        Exclusion Criteria:

          -  Subject taking two or more antihypertensive medications, known contraindication to
             angiotensin-converting enzyme (ACE) inhibitors or alpha- or beta-blocker therapy,
             subject has Type 1 or Type 2 diabetes
Clinical trial NCT00492583 (phase 3, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bifidobacterium lactis (bb-12), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  aged 1-3

          -  attending daycare or preschool centers at least 3 days a week

          -  male or female

          -  parents must speak English or Spanish

          -  subjects or parents/legal guardians who agree to have their child refrain from
             consuming any other yogurts or foods containing probiotics for the duration of the
             study

        Exclusion Criteria:

          -  subjects with developmental delays

          -  subjects with chronic conditions such as diabetes or asthma that require daily
             medication

          -  subjects with birth weight <2500 grams

          -  subjects with strawberry allergies

          -  subjects with active diarrhea

          -  subjects with congenital anomalies

          -  subjects with failure to thrive

          -  subjects with parental belief of lactose intolerance
Clinical trial NCT00483938 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: pegylated-interferon alfa-2a, ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  evidence of CHC;

          -  evidence of hepatitis C non-genotype 2 or 3;

          -  compensated liver disease.

        Exclusion Criteria:

          -  infection with HCV genotype 2 or 3;

          -  history of having received systemic antiviral therapy with activity against CHC <=3
             months prior to start of study;

          -  hepatitis A, hepatitis B or human immunodeficiency virus (HIV) infection;

          -  history or evidence of a medical condition associated with chronic liver disease other
             than CHC.
Clinical trial NCT01087671 (phase 3, status: completed)
Conditions: ocular hypertension, open-angle glaucoma
ICD codes: H40.053, H40.051, H40.052, H40.059, H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: tafluprost
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the
             patient has been using latanoprost 0.005% as his/her prior medication.

          -  Evaluable patients must have ocular surface related symptoms and/or signs with their
             prior medication.
Clinical trial NCT00603577 (phase 3, status: terminated)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: placebo, xaliproden
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=CC=CC=C3C=C2)CC1
Reason stopped: 
    development of product discontinued
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have completed an oxaliplatin-containing chemotherapy regimen post complete surgical
             removal of primary colon tumor no later than 6 weeks before randomization;

          -  Have Grade ≥ 1 PSN, as defined by the NCI-CTCAE version 3.0

          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2;

          -  Blood tests within 14 days prior to randomization: (a) AST (SGOT) and ALT (SGPT) ≤2 x
             upper limit of normal (ULN); (b) serum creatinine ≤1.5 x ULN; (c)HbA1c ≤7%; (d)
             neutrophils ≥1.5x10^9/L ; (e) platelets ≥50x10^9/L; (f) Serum D-dimer within normal
             limits

        Exclusion Criteria:

          -  Pre-existing peripheral neuropathy prior to treatment with oxaliplatin

          -  Receiving any further anti-cancer treatment

          -  History of any recent (≤1 year) thrombo-embolic events and current clinical evidence
             of thrombo-embolism

          -  Unstable cardiac disease

          -  History of significant neurological or psychiatric disorders including dementia or
             seizures,

          -  Active uncontrolled infection

          -  Active disseminated intravascular coagulation

          -  Other serious underlying medical conditions which could impair the ability of the
             patient to participate in the study;

          -  Use of antidepressant/antiepileptic medication (for the treatment of PSN), unless
             commenced before informed consent form signed. The addition of these medications (for
             the treatment of PSN) once the patient has consented is not allowed

          -  Concurrent treatment with any other experimental drugs

          -  Pregnant or breast-feeding women;

          -  Women of childbearing potential must be protected by effective contraceptive methods
             of birth control. Post-menopausal women must have been amenorrheic for at least 12
             months to be considered as having non-childbearing potential

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule. Those conditions
             should be assessed with the patient before registration in the trial.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01106651 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin 100 mg, canagliflozin 300 mg, antihyperglycemic agent(s), placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, N[C@@H](CO)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and may be currently treated with a stable
             regimen of antihyperglycemic agent(s)

          -  Patients in the study must have a HbA1c between >=7 and <=10.0%

          -  Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
Clinical trial NCT01045447 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Treatment with basal insulin regimen (insulin detemir, insulin glargine or neutral
             protamine Hagedorn [NPH] insulin) once daily (OD), for at least 3 months

          -  Ongoing treatment with: metformin with or without other oral antidiabetic drugs (OADs)
             for at least 3 months prior to randomisation

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  BMI maximum 40.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with insulin regimens other than a basal insulin regimen (insulin detemir or
             insulin glargine or NPH insulin) OD within 3 months prior to Visit 1

          -  Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists within 3 months prior
             to visit 1

          -  Current rosiglitazone users

          -  Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Impaired liver function, defined as alanine aminotransferase (ALAT) at least 2.5 times
             upper limit of normal (one retest analysed at the central laboratory within a week of
             receipt of the result is permitted with the result of the last sample being
             conclusive)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous
             cell skin cancer)
Clinical trial NCT01114139 (phase 3, status: completed)
Conditions: iron deficiency anemia
ICD codes: D50.9, D50.0, D50.8
Drugs: ferumoxytol
SMILES: COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Key Inclusion Criteria include:

          1. Males and females ≥18 years of age

          2. Participants with IDA defined as having:

               1. Hemoglobin <10.0 g/deciliter (dL)

               2. Transferrin saturation <20%

          3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral
             iron cannot be used

          4. Female participants of childbearing potential who are sexually active must be on an
             effective method of birth control for at least 1 month prior to screening and agree to
             remain on birth control until completion of participation in the study

        Key Exclusion Criteria include:

          1. History of allergy to IV iron

          2. Allergy to two or more classes of drugs

          3. Participants on dialysis or with an estimated glomerular filtration rate <30
             mL/minute/1.73 m^2

          4. Female participants who are pregnant, intend to become pregnant, are breastfeeding,
             within 2 weeks postpartum, or have a positive serum/urine pregnancy test

          5. Hemoglobin ≤7.0 g/dL

          6. Serum ferritin >600 nanograms/mL
Clinical trial NCT00476099 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: beclomethasone 100 µg plus formoterol 6 µg (chf1535) pmdi, budesonide 200 µg plus formoterol 6 µg dpi, formoterol 12 µg dpi
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of COPD (according to GOLD guidelines)

          -  FEV1 > or equal 30% and < 50% of predicted normal post-bronchodilator (and at least
             0.7 L absolute value)

          -  COPD symptoms for at least 2 years

          -  At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or
             antibiotic treatment and/or need for a visit to an emergency department and/or
             hospitalization) within 2-12 months before screening

          -  Current or previous smoker with a cumulative exposure to smoke of more than 20-pack
             year

        Exclusion Criteria:

          -  Current or past diagnosis of asthma, or any evidence suggestive of asthma

          -  Positive FEV1 reversibility test

          -  Clinically significant or unstable concurrent diseases, including clinically
             significant laboratory abnormalities

          -  Acute COPD exacerbation or lower tract infection and/or treatment with oral or
             injectable corticosteroids and antibiotics in the 2 months before screening or during
             run-in

          -  Long term oxygen therapy
Clinical trial NCT00627640 (phase 3, status: completed)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: safinimide 50-100 mg/day, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

        Male and female between the ages of 30 to 80 years with diagnosis of idiopathic Parkinson's
        Disease of more than 5 years duration, with a Hoehn and Yahr stage of I-IV during an "off"
        phase.

        Be levodopa-responsive and have been receiving treatment with a stable dose of levodopa for
        at least 4 weeks.

        Have motor fluctuations, with >1.5 hours "off" time during the day. Be able to maintain an
        accurate and complete diary (18-hour)

        Exclusion Criteria:

        Patients with medical conditions and/or taking concomitant medications that would have put
        them at risk, interfered with the study evaluations, or made them unable to complete the
        requirements of the study;.

        Be in a late stage of Parkinson's Disease, and experiencing severe, disabling peak-dose or
        biphasic dyskinesia and/or unpredictable or widely swinging fluctuations in their symptoms.

        Current diagnosis of substance abuse or history of alcohol or drug abuse in the past 3
        months.

        Have received treatment with safinamide previously. History of, or current depression
        psychosis (e.g. schizophrenia or psychotic depression) Evidence of dementia or cognitive
        dysfunction. History of allergic response to anticonvulsants, levodopa, or other
        anti-Parkinsonian agents.

        Hypersensitivity or contraindications to MAO-B inhibitors. Ophthalmologic history including
        any of the following conditions: albino subjects, family history of hereditary retinal
        disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis
        pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular
        inflammation (uveitis), or diabetic retinopathy.
Clinical trial NCT00214630 (phase 3, status: completed)
Conditions: acute coronary syndromes
ICD codes: I24.0
Drugs: rosuvastatin calcium, atorvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal
             reperfusion therapy

        Exclusion Criteria:

          -  Previous Q-wave infarct within the last 4 weeks

          -  CK elevation not caused by myocardial injury

          -  uncontrolled hypertension at time of randomization
Clinical trial NCT00635219 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, vortioxetine (lu aa21004), vortioxetine (lu aa21004), vortioxetine (lu aa21004), duloxetine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  MDE as primary diagnosis according to DSM-IV-TR criteria (classification code 296.xx)

          -  Moderate to severe depression

          -  Current MDE duration of at least 3 months

        Exclusion Criteria:

          -  Any current psychiatric disorder other than MDD as defined in the DSM-IV TR

          -  Any substance disorder within the previous 6 months

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT01242228 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, dpp-4 inhibitor
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients receiving with DPP-4 inhibitor mono-therapy for at least 4
             weeks

          -  HbA1c value between 6.5 and 9.5%

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases